1. Search Result
Search Result
Results for "

VCP

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Fluorescent Dye

4

Recombinant Proteins

5

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12861
    CB-5083
    Maximum Cited Publications
    47 Publications Verification

    p97 Cancer
    CB-5083 is a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase/VCP. CB-5083 selectively inhibits p97 through its D2 site with the IC50 of 11 nM .
    CB-5083
  • HY-15713
    NMS-873
    15+ Cited Publications

    p97 Cancer
    NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC50 value of 30 nM.
    NMS-873
  • HY-128870

    Drug-Linker Conjugates for ADC Cancer
    Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates .
    Mal-PEG2-VCP-Eribulin
  • HY-123872
    MSC1094308
    1 Publications Verification

    p97 Cancer
    MSC1094308 is a non-competitive and reversible VPS4B/p97 (VCP) (I/II type AAA ATPase) allosteric inhibitor, with IC50 values of 0.71 μM and 7.2 μM for VPS4B and p97, respectively . MSC1094308 inhibits the D2 ATPase activity by binding to a agentable hotspot of p97. MSC1094308 can be used in study of cancer .
    MSC1094308
  • HY-130084

    ADC Linker Cancer
    Mal-PEG2-VCP-NB is a claevable ADC linker containing a Maleimide group, 2-unit PEG and a VCP NB.
    Mal-PEG2-VCP-NB
  • HY-157508
    VCP Activator 1
    2 Publications Verification

    p97 Others
    VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .
    VCP Activator 1
  • HY-15714
    NMS-859
    1 Publications Verification

    p97 Cancer
    NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
    NMS-859
  • HY-168324

    p97 Others
    UP158 enhances the activity of ATPase, and activates valosin-containing protein (VCP) with an EC50 of 2.57 μM .
    UP158
  • HY-138233

    p97 Neurological Disease Inflammation/Immunology
    KUS121, a valosin-containing protein (VCP, p97) modulator with significant neuroprotective effects, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress .
    KUS121
  • HY-168325

    p97 Others
    UP12 is an ATPase activity activator that activates the ATPase activity of valosin-containing protein (VCP), with an EC50 of 1.24 μM. UP12 is applicable to research related to multisystem proteinopathies .
    UP12
  • HY-139606

    p97 Cancer
    VCP/p97 inhibitor-1 is a potent inhibitor of VCP/p97 (also called Cdc48, CDC-. 48, or Ter94) with an IC50 of 54.7 nM. VCP/p97 inhibitor-1 causes the dysregulation of protein homeostasis and disturbs the degradation of misfolded polypeptides by the ubiquitin-proteasome system (UPS) .
    VCP/p97 inhibitor-1
  • HY-RS15621

    Small Interfering RNA (siRNA) Others

    VCP Human Pre-designed siRNA Set A contains three designed siRNAs for VCP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    VCP Human Pre-designed siRNA Set A
    VCP Human Pre-designed siRNA Set A
  • HY-168323

    p97 Others
    UP163 enhances the activity of ATPase, and activates valosin-containing protein (VCP) with an EC50 of 9.0 μM. UP163 reduces MG-132 (HY-13259)-induced TDP-43 aggregates .
    UP163
  • HY-128871

    Drug-Linker Conjugates for ADC Cancer
    VCP-Eribulin is a bioactive molecule-linker conjugate designed for ADCs (Drug-Linker Conjugates for ADC), formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442). Eribulin is a unique microtubule inhibitor exhibiting antitumor activity. VCP-Eribulin can be utilized for antibody conjugation .
    VCP-Eribulin
  • HY-124776

    p97 Cancer
    NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration. NPD8733 specifically binds to valosin-containing protein (VCP)/p97, a member of the ATPase-associated with diverse cellular activities (AAA+) protein family. NPD8733 has the potential for the research of cancer diseases .
    NPD8733
  • HY-148122

    p97 Cancer
    NW 1028 is a potent VCP/p97 inhibitor. NW 1028 targets the ND1L domain of p97 and inhibits the degradation of a p97-dependent reporter. NW 1028 has good binding affinity with Kd values of 100 and 285 nM for ND1L and full length p97, respectively. NW 1028 has the function of regulating the mitotic spindle of cells .
    NW 1028
  • HY-174984

    p97 Caspase p62 Cancer
    VCP/p97 IN-3 is a VCP/p97 allosteric inhibitor. VCP/p97 IN-3 shows the inhibitory activity against the VCP proteins with an IC50 of 9 nM and the mutant VCP proteins with IC50 of 12 nM (N660K) and 19 nM (V474A/D649A). VCP/p97 IN-3 increases K48-linked ubiquitination and the level of cleaved caspase-3. VCP/p97 IN-3 activates ER-stress and the UPR. VCP/p97 IN-3 inhibits tumor growth in RPMI-8226 cell subcutaneous xenograft mouse models. VCP/p97 IN-3 can be used for the study of multiple myeloma .
    VCP/p97 IN-3
  • HY-RS15623

    Small Interfering RNA (siRNA) Others

    Vcp Rat Pre-designed siRNA Set A contains three designed siRNAs for Vcp gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Vcp Rat Pre-designed siRNA Set A
    Vcp Rat Pre-designed siRNA Set A
  • HY-113608

    Adenosine Receptor Neurological Disease
    VCP171 is a potent adenosine A1 receptor (A1R) positive allosteric modulator (PAM). VCP171 is effective at decreasing excitatory synaptic currents in Lamina II of neuropathic pain model. VCP171 can be used for researching neuropathic pain .
    VCP171
  • HY-174847

    p97 Cancer
    VCP/p97 IN-2 (Compound V13) is a VCP/p97 inhibitor with IC50 of 32 nM for p97. VCP/p97 IN-2 has excellent antitumor activities and significantly inhibits tumor growth in Molm-13 xenograft mice model. VCP/p97 IN-2 can be used for acute myeloid leukemia (AML) research .
    VCP/p97 IN-2
  • HY-160981

    ADC Linker Cancer
    Mal-PEG4-VCP-NB (Compound 17) is a degradable ADC linker containing a maleimide group, 4 PEG units and VCP NB .
    Mal-PEG4-VCP-NB
  • HY-177549

    Drug Derivative ADC Payload Microtubule/Tubulin Apoptosis Cancer
    Fmoc-PEG6-VCP-Eribulin is the derivative of Eribulin (HY-13442). Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules .
    Fmoc-PEG6-VCP-Eribulin
  • HY-177414

    Antibody-Drug Conjugates (ADCs) EGFR Inflammation/Immunology Cancer
    BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .
    BB-1701
  • HY-160982

    ADC Linker Cancer
    Mal-PEG3-VCP-NB (Compund 25c) is a degradable ADC linker containing a maleimide group, 3-unit PEG and VCP NB .
    Mal-PEG3-VCP-NB
  • HY-RS15622

    Small Interfering RNA (siRNA) Others

    Vcp Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vcp gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Vcp Mouse Pre-designed siRNA Set A
    Vcp Mouse Pre-designed siRNA Set A
  • HY-118460

    VCP/p97-IN-PPA

    p97 Cancer
    ACJI-99C (VCP/p97-IN-PPA) is a selective covalent p97/VCP ATPase inhibitor with an IC50 value of 0.6 μM. ACJI-99C binds with p97 active site residues to block ATPase activity. ACJI-99C irreversibly blocks degradation of p97-dependent protein in cells. ACJI-99C inhibits proliferation of cancer cells, including p97 inhibitor-resistant lines. ACJI-99C can be used for the research of colorectal cancer .
    ACJI-99C
  • HY-183257

    Autophagy Beclin1 Reactive Oxygen Species (ROS) p97 Cancer
    ATI-1 is an autophagy initiation inhibitor. ATI-1 targets valosin-containing protein (VCP/p97, disrupts its interaction with UFL1, impairs UFMylation homeostasis associated with VCP, promotes polyubiquitination and degradation of Beclin1, and blocks the formation of early autophagosomes. ATI-1 induces synergistic death of autophagy-dependent malignant tumor cells under nutrient deprivation conditions, accompanied by decreased mitochondrial membrane potential, reduced ROS levels and lysosomal stress. ATI-1 exhibits anti-tumor efficacy in a pancreatic adenocarcinoma xenograft mouse model. ATI-1 can be used for the research of pancreatic adenocarcinoma and lung cancer .
    ATI-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: